Related Experiment Video
Updated: May 5, 2026

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
Valproic acid levels in neurodevelopmental disorders: correlation with CYP and SULT genes using LC-MS/MS
Shada Abutaleb1, Eyad Mallah2, Luay Abu-Qatouseh1
1Faculty of Pharmacy and Medical Sciences, University of Petra, Queen Alia International Airport Road, P.O. Box: 961343, Amman, 11196, Jordan.
Background:
Valproic acid (VPA) is one of the most widely prescribed antiepileptic drugs worldwide, which is used to treat migraines, bipolar disorder, and anxiety. However, VPA is associated with a wide range of side effects. This study evaluates therapeutic drug monitoring (TDM) in individuals with neurodevelopmental disorders. It explores the correlation between valproic acid (VPA) plasma levels and genetic polymorphisms in cytochrome P450 (CYP) enzymes and cytosolic sulfotransferase (SULT) genes.
Methods:
A simple and accurate LC-MS/MS method was developed, validated, and applied in the TDM of 14 individuals on VPA therapy. Plasma VPA levels were measured, and genotyped genes SULT1A1, CYP2D64, CYP2D610, CYP3A5, and CYP2C19*2. Statistical analyses were conducted using SPSS.
Results:
Of the fourteen participants, two had toxic plasma VPA levels (≥ 100 µg/mL), one had a sub-therapeutic level (< 50 µg/mL), and eleven were within or slightly above the therapeutic range (50-100 µg/mL). No significant correlation was observed between VPA plasma concentrations and genotypes of SULT1A1 (p = 0.522), CYP2C192 (p = 0.288), CYP2D64 (p = 0.895), or CYP2D6*10 (p = 0.067). While no direct associations were found, genotype-guided drug therapy remains a promising strategy for optimizing drug efficacy and minimizing toxicity.
Conclusions:
This study highlights the complexity of valproic acid (VPA) therapy in individuals with neurodevelopmental disorders and the limited influence of common genetic polymorphisms in CYP and SULT genes on VPA plasma levels. While therapeutic drug monitoring (TDM) remains an invaluable tool for optimizing VPA therapy, the lack of significant correlations between genetic variants and VPA concentrations suggests that routine pharmacogenetic testing for these specific variants may not be warranted in clinical practice. However, the observed toxic and sub-therapeutic VPA levels emphasize the importance of regular TDM to mitigate risks associated with overdose or insufficient dosing.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
07:05Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay
Published on: September 27, 2024
Related Concept Videos
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Drugs Affecting Neurotransmitter Synthesis
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenomics: Identification of New Drug Targets